---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-304880"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2026-07-15T20:46:28+00:00"
generated_at: "2026-07-15T20:47:20.210830+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aldeyra receives FDA Type A meeting minutes for reproxalap NDA; plans Type D meeting by Q3 2026

## Summary
- Received minutes from Type A meeting with FDA on June 10, 2026 regarding reproxalap NDA for dry eye disease.
- Requested clarification of the minutes from FDA on July 15, 2026.
- Intends to request a Type D meeting to discuss potential resubmission of the NDA.
- Type D meeting expected to be held by the end of the third quarter of 2026.

## SEC filing metadata
- accession: 0001193125-26-304880
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2026-07-15T20:46:28+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312526304880/0001193125-26-304880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312526304880/aldx-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-304880
- JSON: https://secwatch.observer/filing/0001193125-26-304880.json
- Plain text: https://secwatch.observer/filing/0001193125-26-304880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.